| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
National Institute on Drug Abuse (NIDA) Washington DC VA Medical Center Home |
| Information provided by: | National Institute on Drug Abuse (NIDA) |
| ClinicalTrials.gov Identifier: | NCT00000333 |
Purpose
The purpose of this study is to compare the efficacy of benztropine (or DA reuptake inhibitor) with atropine and placebo in affecting stimulated craving to cocaine cues.
| Condition | Intervention | Phase |
|
Cocaine-Related Disorders |
Drug: Benztropine |
Phase II |
| Drug Information available for: | Benztropine Benzatropine methanesulfonate 8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, (1R-(exo,exo))- Cocaine hydrochloride |
| Study Type: | Interventional |
| Study Design: | Treatment |
| Official Title: | Evaluation of Efficacy of Benztropine for Cocaine Craving |
Eligibility
| Ages Eligible for Study: | 22 Years to 48 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Please contact site for information.
Contacts and Locations| United States, District of Columbia | |||||
| Washington DC VA | |||||
| Washington, District of Columbia, United States, 20422 | |||||
| National Institute on Drug Abuse (NIDA) |
| Washington DC VA Medical Center Home |
| Principal Investigator: | Steven Deutsch, M.D. | Washington DC VA |
More Information
| Study ID Numbers: | NIDA-3-0009-2, Y01-3-0009-2 |
| First Received: | September 20, 1999 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00000333 |
| Health Authority: | United States: Federal Government |
|
|
|
|
|
